REFERENCES
- DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200–209.
- Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–661.
- O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87:933–937.
- Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? Bmj. 1993;306:1239–1240.
- de Oliveira BM, Viana MB, Zani CL, Romanha AJ. Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia. Arch Dis Child. 2004;89:785–788.
- Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr. 1992;120:807–811.
- Tamaroff MH, Festa RS, Adesman AR, Walco GA. Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates. J Pediatr. 1992;120:812–817.
- Lansky SB, Smith SD, Cairns NU, Cairns GF, Jr. Psychological correlates of compliance. Am J Pediatr Hematol Oncol. 1983;5:87–92.
- Lau RC, Matsui D, Greenberg M, Koren G. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;30:85–90.
- Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer. 1995;72:1004–1006.
- Smith SD, Rosen D, Trueworthy RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979;43:169–173.
- Tebbi CK, Cummings KM, Zevon MA, Compliance of pediatric and adolescent cancer patients. Cancer. 1986;58:1179–1184.
- Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997;76:365–366.
- Peeters M, Koren G, Jakubovicz D, Zipursky A. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther. 1988;43:228–232.
- Eden OB, Stiller CA, Gerrard MP. Improved survival for childhood acute lymphoblastic leukemia: possible effect of protocol compliance. Pediatr Hematol Oncol. 1988;5:83–91.
- Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8:356–364.
- Levine AM, Richardson JL, Marks G, Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469–1476.
- Pritchard MT, Butow PN, Stevens MM, Duley JA. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol. 2006;28:816–823.
- Kondryn HJ, Edmondson CL, Hill J, Eden TO. Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol. 2010;12:100–108.
- Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760–761.
- Knobel H, Alonso J, Casado JL, Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids. 2002;16:605–613.
- Leplege A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol. 1998;51:1013–1023.
- Sapin C, Simeoni MC, El KhammarM, Reliability and validity of the VSP-A, a health-related quality of life instrument for ill and healthy adolescents. J Adolesc Health. 2005;36:327–336.
- Simeoni MC, Auquier P, Antoniotti S, Validation of a French health-related quality of life instrument for adolescents: the VSP-A. Qual Life Res. 2000;9:393–403.
- Spielberger CD, Gorsuch RL, Lushene RE. STAI manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
- Tournois J, Mesnil F, Kopp JL. Autoduperie et hétéroduperie : un instrument de mesure de la désirabilité sociale. Revue Européenne de Psychologie Appliquée. 2000;50:219–232.
- Rosenbaum JR, Wells CK, Viscoli CM, Altruism as a reason for participation in clinical trials was independently associated with adherence. J Clin Epidemiol. 2005;58:1109–1114.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
- Regnier-Denois V, Poirson J, Nourissat A, Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl). 2011;20:520–527.
- Pellegrini I, Sarradon-Eck A, Soussan PB, Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology. 19:472–479.
- Garner P, Volmink J. Directly observed treatment for tuberculosis. Bmj. 2003;327:823–824.
- Rivard GE, Infante-Rivard C, Hoyoux C, Champagne J. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. Lancet. 1985;2:1264–1266.
- Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271–2276.
- Lightfoot TJ, Johnston WT, Simpson J, Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48:263–269.
- Cote I, Farris K, Feeny D. Is adherence to drug treatment correlated with health-related quality of life? Qual Life Res. 2003;12:621–633.